Aadi Bioscience enters manufacturing agreement with Fresenius Kabi for Fyarro

Whitehawk Therapeutics, Inc.

Fresenius Kabi to manufacture Fyarro (sirolimus protein-bound) for Aadi under a purchase-order basis.
Agreement effective through Dec 31, 2022; covers clinical and commercial supply for US and Canada.
Aadi has minimum purchase obligations; failure triggers additional payment to Fresenius Kabi.
Price fixed but subject to increase under specified circumstances; includes labeling/packaging services.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.